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Abstract
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for
evaluating health-related quality of life data in oncology clinical trials. The different analyses consistently
showed that patients’ overall global health status/quality of life status was not impaired by active treatment with
nintedanib versus placebo, and that patients perceived some benefits with nintedanib compared with placebo.
Introduction: We used European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) data from the LUME-Colon 1 study to illustrate different methods of statistical analysis for health-
related quality of life (HRQoL), and compared the results. Patients and Methods: Patients were randomized 1:1 to
receive nintedanib 200 mg twice daily plus best supportive care (n ¼ 386) or matched placebo plus best supportive
care (n ¼ 382). Five methods (mean treatment difference averaged over time, using a mixed-effects growth curve
model; mixed-effects models for repeated measurements (MMRM); time-to-deterioration (TTD); status change; and
responder analysis) were used to analyze EORTC QLQ-C30 global health status (GHS)/QoL and scores from functional
scales. Results: Overall, GHS/QoL and physical functioning deteriorated over time. Mean treatment difference slightly
favorednintedanibover placebo for physical functioning (adjustedmean, 2.66; 95%confidence interval [CI], 0.97-4.34) and
social functioning (adjusted mean, 2.62; 95% CI, 0.66-4.47). GHS/QoL was numerically better with nintedanib versus
placebo (adjusted mean, 1.61; 95% CI, 0.004 to 3.27). MMRM analysis had similar results, with better physical
functioning in the nintedanib group at all timepoints. There was no significant delay in GHS/QoL deterioration (10%)
and physical functioning (16%) with nintedanib versus placebo (TTD analysis). Status change analysis showed a higher
proportion of patients with markedly improved GHS/QoL and physical functioning in the nintedanib versus placebo
groups. Responder analysis showed a similar, less pronounced pattern. Conclusion: Analyses of EORTC QLQ-C30
data showed that HRQoL was not impaired by treatment with nintedanib versus placebo. Analysis and interpretation
of HRQoL endpoints should consider symptom type and severity and course of disease.
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LUME-Colon 1 QoLIntroduction alanine aminotransferase (8%) and aspartate aminotransferase (8%)
Patient-reported outcomes (PROs) are an important consider-
ation in the delivery of clinical care, clinical trial design, and
comparative effectiveness research in oncology. Regulatory bodies
such as the United States Food and Drug Administration and the
European Medicines Agency encourage the inclusion of patient-
focused clinical outcome assessments in clinical trials to support
drug approvals and labeling claims.1 PROs are also integrated into
health technology assessments to reflect clinical benefit from the
patient’s perspective.2
In trials that include patients with advanced cancer, including
those with metastatic colorectal cancer (CRC), the assessment and
analysis of PROs present several challenges. Generally, there is an
overall deterioration in patient health and quality of life (QoL)
rather than an improvement, owing to the clinical course of the
disease.3 In addition, because of disease progression, there is a high
dropout rate, which results in incomplete data sets.3 The dropout
may often differ between treatment arms, which complicates the
issue of missing data.4 Finally, health-related quality of life
(HRQoL) scales are often multidimensional and include several
subscales, which can lead to complex result patterns.5
The European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) is often used to
collect data onHRQoL and symptom burden in patients with cancer.6
However, these data can be analyzed using a variety of methods, as
exemplified in different clinical studies of CRC (see Supplemental
Table 1 in the online version).7-18 These statistical methods can be
broadly allocated to 2 types: those that assess group means and those
that assess clinically relevant changes at the level of the patient. The
first type of method ‒ group mean methods ‒ treat the data as
continuous endpoints, and include longitudinal models such asmixed-
effects growth curve models and mixed-effects models for repeated
measurements (MMRM). The second type of method requires defi-
nition of a minimal clinically important difference (MCID) at the level
of the individual patient, including time-to-deterioration (TTD),
distribution of patients who improved, patients who were stable or
worsened from baseline, and responder analysis.19
Nintedanib is an oral, twice-daily (bid), triple angiokinase in-
hibitor that targets vascular endothelial growth factor receptors 1 to
3, platelet-derived growth factor receptors a/b, and fibroblast
growth factor receptors 1 to 3, as well as RET and Flt3
receptors.20,21
The randomized, double-blind, placebo-controlled, phase III
LUME-Colon 1 study (ClinicalTrials.gov identifier
NCT02149108) investigated the efficacy and safety of nintedanib
plus best supportive care (BSC) versus placebo plus BSC for the
treatment of patients with metastatic CRC refractory to standard
therapies.22 Co-primary endpoints were progression-free survival
(PFS) and overall survival (OS).22 PFS by independent central re-
view was significantly longer with nintedanib than with placebo
(hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.49-0.69;
P < .0001),22 whereas OS was not (HR, 1.01; 95% CI, 0.86-1.19;
P ¼ .8659).22 The safety profile of nintedanib was consistent with
safety data previously reported in early-phase CRC studies.23,24 In
LUME-Colon 1, the most frequent grade  3 adverse events (AEs)
in the nintedanib group were liver-related AEs, mainly increasedClinical Colorectal Cancer December 2019levels and fatigue. The most common AEs leading to treatment
discontinuation in the nintedanib group were fatigue (n ¼ 8),
followed by asthenia, decreased appetite, and malignant neoplasm
progression (all n ¼ 6).22 The LUME-Colon 1 study incorporated
assessments of PROs, including HRQoL, as a further endpoint.
The objectives of this evaluation were: (1) to perform different
exploratory analyses of EORTC QLQ-C30 data from the LUME-
Colon 1 study and (2) to discuss possible interpretations of these




The study design of LUME-Colon 1 has been reported previ-
ously.22 LUME-Colon 1 enrolled adults with histologically or
cytologically confirmed metastatic or locally advanced CRC that was
not amenable to curative surgery and/or radiotherapy. Patients were
required to have progressed on approved standard therapies or to
have experienced unacceptable toxicity.22 Study participants were
randomized 1:1 to receive treatment with either nintedanib 200 mg
bid plus BSC (n ¼ 386) or placebo bid plus BSC (n ¼ 382) in 21-
day cycles.22 In this study, BSC was defined as the best palliative
care, excluding specific anticancer treatments, according to the in-
vestigator’s decision.
PRO Measures
PROs, including HRQoL, were evaluated using EORTC QLQ-
C30 and the EuroQoL 5-dimensions questionnaire (EQ-5D). The
EQ-5D was included for health economic analyses, and so the
analyses in this report will only focus on the EORTC QLQ-C30
component. The EORTC QLQ-C30 consists of multi-item scales
and single-item measures as follows: 5 functional scales (physical,
role, emotional, cognitive, and social functioning)25; 3 symptom
scales (fatigue, pain, and nausea/vomiting)25; 6 single questions
(assessing dyspnea, appetite loss, sleep disturbance, constipation,
diarrhea, and the perceived financial impact of disease and treat-
ment)25; and global health status (GHS)/quality of life (QoL)
scale.25
We report the GHS/QoL scale (consisting of 2 items) and the 5
functional scales (see Supplemental Table 2 in the online version).25
Questionnaires were completed at screening, on day 1 of each 21-
day cycle, at the end of treatment visit, 28 days after the last
treatment, and at follow-up for disease progression. Scoring fol-
lowed the EORTC QLQ-C30 scoring algorithm.25 A linear trans-
formation was used to standardize raw scores from 0 to 100.25 A
higher score on the GHS/QoL scale and the functioning scales
indicated a higher (‘better’) level of functioning and HRQoL.25
Statistical Analyses
All analyses were descriptive and exploratory. P values were
nominal and not adjusted for multiple testing. In line with the
primary PFS and OS analysis of the trial, all models were adjusted
for the following stratification factors: regorafenib pretreatment;
time from onset of metastatic disease; and region. Five different
methods were used to analyze the EORTC QLQ-C30 data.
Heinz-Josef Lenz et alMethods Using Group Means
These methods analyze the scales as continuous endpoints (lon-
gitudinal analyses), compute the mean of each treatment arm, and
compare these means (Table 1). We used 2 of these methods to
analyze data from LUME-Colon 1: the mixed-effects growth curve
model and the MMRM.
Mean Treatment Difference for GHS/QoL and Functional Scale
Scores Based on Mixed-effects Growth Curve Models. This method
assessed changes in scores over time, with the average profile over
time for each endpoint described by a piecewise linear regression
model. For this particular study, weeks 3, 6, and 9 were selected to
allow the slope to change; many patients were anticipated to drop
out by week 12 owing to disease progression. All available data were
used to fit the model.
Each model included 2 random effects: intercept and slope. To fit
the model, the actual timepoints of the assessments were used. The
mean score for each HRQoL endpoint was calculated from the area
under the estimated growth curve up to the median follow-up time,
and was interpreted as the average HRQoL score until the median
follow-up time per group.
Mean Treatment Difference for GHS/QoL and Functional Scale
Scores Based on MMRM. This longitudinal model also assessed
changes in scores over time. It shows a pairwise comparison of mean
scores between treatment arms for each timepoint/visit. The model
included fixed categorical effects of treatment, stratification factors,
visit, treatment-by-visit interaction, baseline, and baseline-by-visit
interaction. The effects of visit and treatment-by-visit interactionTable 1 Summary of Methods That Can Be Used to Assess EORTC
Methods Des
Methods using group means
Mixed-effects growth curve models  Mean score over time, typically asses
MMRM  Estimates fixed effects: a visit effect,
visit interaction. Random effects (indiv
 This model accounts for the associatio
same patient28
Methods assessing clinically relevant
changes at the patient level
TTD  Survival-based analyses19
 Describes time from baseline until firs
at least one MCID unit3
 Patients with no deterioration before t
at the time of the last follow-up or th
TUDD  Survival-based analysis19
 Describes time from baseline until defi
point there is no improvement of > 1
or if the patient dropped out after det
Status change  Analysis of proportion of patients impr
by change  MCID
 Comparison of percentage of patients
Responder analysis  Comparison of proportion of responde
mean improvement of  1 MCID duri
Time to improvement  Time until first improvement  MCID
Abbreviations: EORTC QLQ-C30 ¼ European Organization for the Research and Treatment of Cancer
important difference; MMRM ¼ mixed-effects model for repeated measurements; TTD ¼ time to dallowed the model to incorporate time profiles without assuming a
specific shape over time, in contrast to the piecewise linear shape in
the mixed-effects growth curve model. The analysis was restricted to
weeks 3, 6, 9, and 12. An unstructured covariance matrix was used
to model the within-patient measurements.
Methods Assessing Clinically Relevant Changes at the
Patient Level
These methods show differences between treatment arms based
on the proportion of patients with an on-treatment improvement or
a delay in worsening of the disease (Table 1).
Deteriorations Analyzed as TTD. In this evaluation, TTD was
considered to be the time elapsed until a minimal clinically
important deterioration (ie, of 10 points from baseline) occurred.26
Cox regression, log-rank tests, and Kaplan-Meier curves were used
as standard analysis methods. A stratified log-rank test, using the
same stratification as for PFS, was used to investigate whether a
delay in progression translated into a delayed worsening in HRQoL.
Patients who died before their condition deteriorated were assumed
to have deteriorated at the time of death. If a patient dropped out
without experiencing deterioration or death, they were censored in
this analysis. This analysis assumed that censoring was independent
of deterioration in HRQoL.
Improvements Analyzed as Status Change (Improved, Stable, or
Worsened). Status change assessed the proportion of patients who
improved (even if this was temporary), stabilized, or worsened






sed at selected timepoints No Over time
an arm effect, and a treatment-by-
idual trends) are also introduced28
n of repeated measures made on the
No Over time
t instance of patient deterioration of
hey are lost to follow-up are censored
e last HRQoL assessment3
Yes One event
nitive deterioration (ie, after which
MCID unit compared with baseline value
erioration, resulting in missing data)3
Yes One event
oving, worsening, or being stable, defined
being stable and/or improved vs. worsened
Yes One event
rs, defined as patients with
ng follow-up time of the study30
Yes Over time
Yes One event
Quality of Life Questionnaire; HRQoL ¼ health-related quality of life; MCID ¼ minimal clinically
eterioration; TUDD ¼ time until definitive deterioration.
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272 -Patients were categorized as having perceived improvement at least
once (improvement of  10 units from baseline at any time during
the study), regardless of potential worsening at other timepoints;
worsened (decrease of  10 units and no improvement at any time
during the study); or remained stable (neither showing improve-
ment nor deterioration of  10 units at any time during the study).
This endpoint was analyzed as a binary endpoint, comparing the
proportion of patients with improvements between treatment
groups using logistic regression.
Responder Analysis. In contrast to the status change analysis, the
responder analysis was based on the average change from baseline
over the entire observation period. A responder was defined as a
patient who achieved an average  10-point increase in score from
baseline over the duration of follow-up. The responder analysis
compared the proportions of patients in each treatment arm, as was
done for status change analysis.
Results
Patient Population and Baseline Characteristics
Patient demographics and baseline clinical characteristics have
been reported previously and were mostly balanced between treat-
ment groups.22
Completion of EORTC QLQ-C30 Questionnaires
During the first 12 cycles of treatment, EORTC QLQ-C30
questionnaires were completed by  87.5% of patients. In the
nintedanib plus BSC arm and the placebo plus BSC arm, 82.7%
and 80.4% of patients, respectively, completed questionnaires at the
end of treatment.Figure 1 Longitudinal Analysis: Mean Treatment Difference for GHS
Abbreviations: CI ¼ confidence interval; GHS ¼ global health status; Q ¼ question; QoL ¼ quality
Clinical Colorectal Cancer December 2019Mean Treatment Difference for GHS/QoL and Functional
Scale Scores
Baseline mean scores for GHS/QoL and physical functioning
were comparable between treatment arms. Baseline mean scores for
GHS/QoL were 64.9  19.6 versus 65.3  20.5 for the nintedanib
and placebo arms, respectively. Baseline mean scores for physical
functioning were 80.1  18.4 in the nintedanib arm and
79.8  17.9 in the placebo arm.
Mean treatment difference (ie, the difference in the area under
the curve in the mixed-effects growth curve model, adjusted for
stratification factors) favored nintedanib plus BSC over placebo plus
BSC for physical functioning and social functioning. Numerical
improvements were reported for GHS/QoL, role, and emotional
and cognitive functioning (Figure 1).
MMRM Analysis
Numerical improvements in the GHS/QoL scores and all func-
tioning scores were reported in the nintedanib group versus the
placebo group (Figures 2 and 3). Only physical functioning showed
a significant between-group difference at all timepoints (Figure 3).
Overall, a worsening in GHS/QoL and physical functioning was
observed from weeks 3 to 12; this illustrates the expected, natural
course of the disease (Figure 2).
There were significant between-group differences in physical
functioning in favor of the nintedanib group at weeks 3, 6, 9, and
12 (Figure 3B).Treatment differences were similar between weeks 3
to 6 and 9 to 12, respectively, with larger differences in magnitude
reported later in therapy (ie, at weeks 9 and 12) (Figure 3B).
Between-treatment group differences in emotional functioning
scores followed a similar trend to those observed for physical/QoL and Functional Scale Scores
of life.
Figure 2 MMRM Analysis: Adjusted Mean Score of GHS/QoL and Physical Functioning. Figure Without Break in Axis Is Shown Inset.
Baseline Values Are From Longitudinal Analysis and Are Shown for Reference. Error Bars Are ± SE
Abbreviations: GHS ¼ global health status; MMRM ¼ mixed-effects model for repeated measurements; QoL ¼ quality of life.
Heinz-Josef Lenz et alfunctioning, although between-group differences were only signifi-
cant at week 9 (see Supplemental Table 3 in the online version)
(Figure 3D). Between-group differences in cognitive functioning
and social functioning are shown in Figures 3E and F, respectively.
In contrast to other endpoints, there were no significant between-
treatment group differences in role functioning at any of the
timepoints (see Supplemental Table 3 in the online version)
(Figure 3C).
TTD
There was a general trend in favor of the nintedanib group
compared with the placebo group for all functional scales apart from
role functioning; there was also a trend in favor of the nintedanib
group for GHS/QoL (Figures 4 and 5). Cognitive functioning
showed a significant difference between treatment arms (Figure 5).
Status Change (Proportion of Patients Improved vs. Not
Improved [Stable or Worsened])
The proportion of patients with improved GHS/QoL and
physical functioning was significantly higher in the nintedanib
group than in the placebo group (Figure 6), with an odds ratio
equating to an improvement of 56% and 54%, respectively. There
was a general trend in favor of nintedanib versus placebo for allother functional scales, with cognitive and social functioning also
showing a significant difference between treatment groups
(Figure 6).
Responder Analysis
On average over the treatment period, only a small proportion of
patients perceived an improvement in HRQoL and functioning
scores (5.3%-13.8% in the placebo arm and 6.9%-17.2% in the
nintedanib arm) (see Supplemental Table 4 in the online version).
Nevertheless, the nintedanib group had a somewhat higher response
rate in GHS/QoL and physical functioning scores than the placebo
group, with an odds ratio equating to an improvement of 46% and
32%, respectively (see Supplemental Table 4 in the online version).
There were higher responder rates with nintedanib versus placebo in
the cognitive and social functioning scales than in other functional
scales, equating to a relative improvement of 54% and 29%,
respectively (see Supplemental Table 4 in the online version).
However, the confidence intervals included 1 for all scores.
Discussion
The LUME-Colon 1 study failed to meet both co-primary
endpoints: there was no survival benefit and a significant but
modest increase in PFS with nintedanib versus placebo. PRO dataClinical Colorectal Cancer December 2019 - 273
Figure 3 MMRM Analysis: Mean Treatment Difference. Plots Shown Are Placebo-corrected Means With Upper and Lower Confidence
Intervals
Abbreviations: GHS ¼ global health status; MMRM ¼ mixed-effects model for repeated measurements; QoL ¼ quality of life.
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274 -from the study, reported here, indicate that patients’ overall
GHS/QoL status and physical functioning were not impaired, and
were improved in some respects, by treatment with nintedanib
compared with placebo.Clinical Colorectal Cancer December 2019Overall, results from the different methods of analysis showed an
apparent benefit of treatment with nintedanib versus placebo in
various PROs, in particular in physical functioning. The longitu-
dinal analysis using the mixed-effects growth curve model included
Figure 4 Kaplan-Meier Curves of Time to Deterioration of GHS/QoL Score (A) and Physical Functioning Score (B)
Abbreviations: CI ¼ confidence interval; GHS ¼ global health status; HR ¼ hazard ratio; QoL ¼ quality of life.
Heinz-Josef Lenz et althe first 9 weeks of treatment. Results showed that average physical
functioning was better with nintedanib than with placebo during
this time. MMRM confirmed this pattern through weeks 3, 6, 9,
and 12, with larger improvements at weeks 9 and 12. The ‘status
change’ analysis, which focused on temporary but clinically relevant
changes in individual patients at specific timepoints during therapy,
supported the outputs of the longitudinal analysis. It showed that
there were statistically significant and clinically meaningful im-
provements in physical functioning, GHS/QoL, and cognitive and
social functioning with nintedanib versus placebo.
In contrast to the status change analysis, the responder analysis
had a stronger criterion of a mean improvement of  10 points
averaged over all timepoints in the study. This analysis did not show
a statistically significant difference between treatment groups,
perhaps reflecting the short time to disease progression in this study
population. TTD in physical functioning was numerically longer
with nintedanib than with placebo, although there was no signifi-
cant difference between treatment arms. Data from the individualitems of the physical functioning assessment indicate that patients
experienced delayed deterioration in their ability to undertake
strenuous activity (eg, heavy lifting) and take a walk outside, and in
their need for help when eating and dressing (see Supplemental
Figure 3 in the online version). Looking at individual items in
this way can contribute to our understanding of patients’ experience
while on treatment.
The variety of statistical methods used to analyze data obtained
using EORTC QLQ-C30 can make it difficult to interpret the likely
impact of those data in the clinic.27 This lack of standards for
analyzing PRO and HRQoL data has been recognized, and a con-
sortium initiative (the Setting International Standards in Analysing
Patient-Reported Outcomes and Quality of Life Endpoints Data) has
been established. This consortium, directed by the EORTC, aims to
establish recommendations on how to standardize the analysis of
HRQoL and other PRO data in randomized cancer drug trials.27
The outputs of the different statistical methods used to analyze
EORTC QLQ-C30 in this study demonstrate that there areClinical Colorectal Cancer December 2019 - 275
Figure 5 TTD: GHS/QoL and Functioning Scales. Results Presented on a Logarithmic Scale to Base 4
Abbreviations: CI ¼ confidence interval; GHS ¼ global health status; HR ¼ hazard ratio; Q ¼ question; QoL ¼ quality of life; TTD ¼ time to deterioration.
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276 -different ways to evaluate what patients experience in everyday life
while on treatment. Interpretation of these different analyses
requires context: in this study, it is important to note the rapid
deterioration in QoL and physical functioning experienced by pa-
tients in both treatment arms, and the short PFS. Clinical inter-
pretation of the results of these methods requires us to bear in mind
the strengths and limitations of each one, as follows.
Mixed-effects Growth Curve and MMRM Models
These analyses offer an overall comparison of the treatment arms,
taking the longitudinal course of the disease and treatment into
account. Both models assume that data are missing at random. This
assumption is violated if patients who drop out have worse HRQoL
scores than those who continue in the study, which is a common
scenario. However, a key advantage of these methods is that group
means can be analyzed without a defined MCID. Furthermore, all
the information from the questionnaire can be analyzed directly,
without the need to classify the collected data as an improvement or a
deterioration. In addition, mixed-effects growth curve models are able
to incorporate the actual timepoint of a measurement, even if there
are many assessments during long-term follow-up, whereas the
MMRM uses the planned timepoints of the assessments. MMRM is
regarded as a well-established and robust approach, particularly if
there are missing data (as long as those data are missing at random).28
One disadvantage of mixed-effects growth curve and MMRM
models is that the outputs can be difficult to interpret: clinicallyClinical Colorectal Cancer December 2019relevant criteria for comparing group means are needed, which are
often more difficult to substantiate than a MCID on the individual
patient level. Another disadvantage is that during long-term follow-
up, the assignment of timepoints to visits might be challenging if
clinic visits are delayed.
TTD
Among the strengths of TTD is its use of MCID. For well-
established questionnaires such as the EORTC QLQ-C30, widely
accepted MCIDs are available. This makes TTD a clinically relevant
measure that is easy to interpret and apply. TTD is a particularly
meaningful analysis if a deterioration in HRQoL is expected long
term and the therapy tested is expected to delay progression and
deterioration of HRQoL. Analysis of TTD mirrors the analysis of
PFS, complementing the interpretation of this common endpoint in
oncology trials. Finally, TTD analyses can be adjusted using
censoring to take into account missing data, patient deaths, and
changes in patients’ individual perception of their QoL over time.28
One of the disadvantages of TTD analyses is the need to clearly
define what constitutes deterioration.28 Another point is that the
analysis may be less robust if patients drop out because of pro-
gressive disease but do not experience deterioration according to the
MCID; this would mean that censoring could introduce bias into
the analysis. Furthermore, when interpreting the results of a TTD
analysis, it is necessary to keep in mind that only the time to first
deterioration is taken into account ‒ information on long-term
Figure 6 Status Change: Proportion of Patients With Improvement in Functional Scales and GHS/QoL Scores. 1Odds Ratio >1 Favors
Nintedanib; 2P Value Corresponds to Patients Who Improved vs. Patients Who Did Not Improve (ie, Stable Plus Worsened
Categories Combined)
Abbreviations: GHS ¼ global health status; QoL ¼ quality of life.
Heinz-Josef Lenz et altreatment effects after the first deterioration is not considered.
Hence, TTD analysis might be most appropriate if the first dete-
rioration is of interest, or if the natural course of disease suggests a
continuous deterioration. Finally, TTD analyses assume that
censoring is non-informative; if data are not missing at random
before a deterioration occurs, this assumption is violated.
Status Change
The main advantage of the status change method is its simplicity:
it looks at clinically meaningful changes in HRQoL at the level of
each individual patient. Depending on how status change is defined,
even a single measured change from baseline can be sufficient to
classify a patient as ‘improved.’ In severe, incurable diseases, the
overall course of the disease is one of deterioration, and so a status
change analysis can reveal at least temporary improvements that may
be experienced by some patients.
A potential disadvantage of this method is that it is susceptible to
bias in favor of the treatment arm that had a longer follow-up.
Status change analyses are therefore most appropriate in studies
that have similar expected observation periods in all treatment
groups.
Responder Analysis
Responder analyses require a mean improvement over all time-
points of at least the MCID. It is more stringent than the status
change analysis, and does not just take into account temporary
improvements. It is appropriate if a mean improvement can be
expected over the entire course of study treatment.Disadvantages of responder analyses include that the definition of
response needs to be based on a validated MCID.29 In addition, this
type of analysis has reduced power compared with an analysis based
on continuous data; also, it is more challenging to achieve a
response with longer follow-up if there is a fast deterioration in
HRQoL owing to the underlying disease.
General Points on the Interpretation of Different Analyses
In some cases, the interpretation of methods that are based on
clinically relevant changes can be misleading. For example, patients
who experience a different QoL profile over time could have the same
TTD if they reach theMCID at the same timepoint (see Supplemental
Figure 1 in the online version). Alternatively, a patient whose disease
status deteriorates rapidly but then improves could have a shorter TTD
than a patient whose QoL remains stable for some time but then
deteriorates (see Supplemental Figure 2 in the online version). Simi-
larly, a patient with a short improvement in QoL who drops out
because of disease progression and then has a rapid deterioration in
HRQoL after the end of follow-up could be categorized as a
‘responder.’ The potential for misinterpretation highlights the
importance of analyzing HRQoL data using different, complementary
methods to obtain an accurate picture of patients’ experiences.
Analysis of QoL endpoints needs to be meaningful in context,
which includes consideration of the type and severity of symptoms
and the course of treatment and disease. In this study, the patient
population had late-stage CRC, with a high symptom burden, fast
deterioration of QoL, and short survival. Delay of progression and
deterioration while maintaining HRQoL and functioning is theClinical Colorectal Cancer December 2019 - 277
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278 -primary goal of therapy. Given the considerations listed in this
Discussion, analysis of TTD, complemented by a longitudinal
analysis and an analysis of status change, may be most useful for
characterizing patients’ experience on study treatment.
Conclusions
PRO data from LUME-Colon 1 showed that the overall GHS/
QoL status was not impaired by active treatment with nintedanib,
and that patients perceived some HRQoL benefits with nintedanib
compared with placebo. This is in line with the modest PFS benefit
observed in the study. Careful consideration and comparison of
different methods of analysis of EORTC QLQ C-30 are required in
settings such as metastatic refractory CRC in order to support
clinical interpretation and application of findings.
Clinical Practice Points
 PROs are an essential part of clinical trials, and in particular play
a key role in interpreting the benefit of a novel treatment from
the patient’s perspective.
 We used EORTC QLQ-C30 data from the LUME-Colon 1
study to compare and contrast the different statistical methods
that can be used to evaluate these types of data. The different
analyses complement each other.
 These analyses show that, in LUME-Colon 1, overall GHS/QoL
status was not impaired by active treatment with nintedanib
compared with placebo. In fact, patients even perceived some
benefits with nintedanib compared with placebo, in particular
with regard to physical functioning.
 However, there was no survival benefit and only a modest in-
crease in PFS with nintedanib versus placebo in this study.
 Careful consideration and comparison of different methods of
analysis of EORTC QLQ C-30 are required in settings such as
metastatic refractory CRC in order to support clinical interpre-
tation and application of findings.Acknowledgments
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279.eSupplemental DataSupplemental Figure 1 Individual Patient Profiles Over Time With Same TTD
Abbreviations: BL ¼ baseline; MID ¼ minimal important difference; TTD ¼ time to deterioration.
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Supplemental Figure 2 Individual Patient Profiles With Short and Long TTD
Abbreviations: BL ¼ baseline; MID ¼ minimal important difference; TTD ¼ time to deterioration.
Supplemental Figure 3 TTD: Physical Functioning Scale e Individual Items
Abbreviations: CI ¼ confidence interval; EORTC QLQ-C30 ¼ European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; HR ¼ hazard ratio; Q ¼ question; TTD ¼ time
to deterioration.
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to Specified Timepoint TTD TUDD
Longitudinal
Analysis Responder Status Change
Yamaguchi et al, 20177 and Lang et al, 201331
Cetuximab plus chemotherapy: CRYSTAL study
3 3 3 3
Pinto et al, 20168
Cetuximab plus chemotherapy: ObservEr Study
3 3
Quidde et al, 20169
Fluoropyrimidine plus bevacizumab: AIO KRK 0207 trial
3 3 3 3
Hamidou et al, 201610 FOLFOX4 versus sequential dose-dense
FOLFOX7 followed by FOLFIRI: MIROX trial
3
Grothey et al, 201318 and Yoshino et al, 201511
Regorafenib: CORRECT trial
3 3
Qin et al, 201512
Regorafenib: CONCUR trial
3 3
Thaler et al, 201213
Panitumumab plus FOLFIRI
3 3
Au et al, 200914
Cetuximab: NCIC CTG and AGITG CO.17 trial
3 3 3 3
Tol et al, 200915
Cetuximab plus chemotherapy and bevacizumab
3
Sobrero et al, 200816
Cetuximab plus irinotecan: EPIC trial
3 3
Rosati et al, 200517
Oxaliplatin plus tegafur/uracil and oral folinic acid
3













Supplemental Table 3 MMRM Analysis
Endpoint
Difference From Placebo
Adjusted Mean (SE) 95% CI
GHS/QoL (Q29, Q30)
Week 3 2.5 (1.3) 0.0 to 4.9
Week 6 2.5 (1.4) 0.3 to 5.3
Week 9 0.2 (1.9) 3.4 to 3.9
Week 12 0.3 (2.2) 4.0 to 4.6
Physical functioning (Q1-Q5)
Week 3 2.6 (1.0) 0.7 to 4.5
Week 6 3.0 (1.4) 0.4 to 5.7
Week 9 5.9 (1.7) 2.6 to 9.3
Week 12 4.5 (2.2) 0.2 to 8.8
Role functioning (Q6-Q7)
Week 3 1.0 (1.6) 2.1 to 4.2
Week 6 1.6 (1.9) 2.0 to 5.3
Week 9 1.3 (2.3) 3.2 to 5.8
Week 12 1.2 (2.9) 4.4 to 6.8
Emotional functioning (Q21-Q24)
Week 3 0.5 (1.2) 1.8 to 2.8
Week 6 0.6 (1.4) 2.1 to 3.3
Week 9 4.2 (1.6) 1.1 to 7.4
Week 12 3.8 (2.0) 0.0 to 7.7
Cognitive functioning (Q20, Q25)
Week 3 1.6 (1.1) 0.7 to 3.8
Week 6 1.0 (1.3) 1.6 to 3.6
Week 9 5.7 (1.6) 2.7 to 8.8
Week 12 2.1 (2.0) 1.9 to 6.1
Social functioning (Q26, Q27)
Week 3 2.9 (1.5) 0.0 to 5.8
Week 6 3.8 (1.7) 0.5 to 7.2
Week 9 4.1 (2.2) 0.3 to 8.4
Week 12 1.3 (2.6) 3.8 to 6.4
Results are from an MMRM model. Fixed effects include treatment, stratification factors, visit, treatment-by-visit interaction, baseline, and baseline-by-visit interaction. Number of patients contributing
to the MMRM model in each treatment group: placebo, n ¼ 356; nintedanib, n ¼ 360.
Abbreviations: CI ¼ confidence interval; GHS ¼ global health status; MMRM ¼ mixed-effects model for repeated measurements; Q ¼ question; QoL ¼ quality of life; SE ¼ standard error.
Supplemental Table 2 Predefined HRQoL Measures of Interest in LUME-Colon 1
Scale Item/Question
GHS/QoLa 1 How would you rate your overall health during the past week?
2 How would you rate your overall QoL during the past week?
Physical functioningb 1 Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?
2 Do you have any trouble taking a long walk?
3 Do you have any trouble taking a short walk outside of the house?
4 Do you need to stay in bed or on a chair during the day?
5 Do you need help with eating, dressing, washing yourself, or using the toilet?
Abbreviations: GHS ¼ global health status; HRQoL ¼ health-related quality of life; QoL ¼ quality of life.
aFor both questions, the patient can circle a number between 1 (very poor) and 7 (excellent).
bThere are 4 response categories: 1 ¼ not at all, 2 ¼ a little, 3 ¼ quite a bit, and 4 ¼ very much. Questionnaires were completed at timepoints specified in the protocol: at screening, day 1 of each
21-day cycle, at the end of treatment visit, at the end of the residual period, and at follow-up for disease progression.
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Supplemental Table 4 Responder Analysis
Number of Responders (%)
Nintedanib vs. Placebo
Odds Ratio (95% CI)Endpoint Placebo (Na [ 356) Nintedanib (Na [ 360)
GHS/QoL
GHS/QoL (Q29, Q30) 35 (9.8) 50 (13.9) 1.46 (0.92-2.31)
Functional scales
Physical functioning (Q1-Q5) 19 (5.3) 25 (6.9) 1.32 (0.71-2.45)
Role functioning (Q6, Q7) 39 (11.0) 40 (11.1) 1.01 (0.63-1.61)
Emotional functioning (Q21-Q24) 45 (12.6) 46 (12.8) 1.00 (0.64-1.55)
Cognitive functioning (Q20, Q25) 31 (8.7) 46 (12.8) 1.54 (0.95-2.49)
Social functioning (Q26, Q27) 49 (13.8) 62 (17.2) 1.29 (0.86-1.94)
Results are from fitting a generalized linear regression model adjusted for treatment and stratifications factors used at randomization and a logit link (odds ratio). An odds ratio > 1 indicates a benefit
to nintedanib.
Abbreviations: CI ¼ confidence interval; GHS ¼ global health status; Q ¼ question; QoL ¼ quality of life.
aNumber of patients with baseline and at least one post-baseline assessment.
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